Kelly Financial Services’s PharmaCyte Biotech PMCB Stock Holding History

Kelly Financial Services’s Portfolio PMCB Stock Details PMCB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-234	Closed	-$459	–	581
2024 Q2	$459	Hold	234	–	–	﹤0.01%	710
2024 Q1	$555	Hold	234	–	–	﹤0.01%	715
2023 Q4	$505	Hold	234	–	–	﹤0.01%	704
2023 Q3	$491	Hold	234	–	–	﹤0.01%	683
2023 Q2	$669	Hold	234	–	–	﹤0.01%	635
2023 Q1	$681	Hold	234	–	–	﹤0.01%	611
2022 Q4	$686	Hold	234	–	–	﹤0.01%	584
2022 Q3	$562	Sell	234 -28	-11%	-$71	﹤0.01%	602
2022 Q2	$587	Hold	262	–	–	﹤0.01%	598
2022 Q1	$603	Hold	262	–	–	﹤0.01%	595
2021 Q4	$655	Hold	262	–	–	﹤0.01%	613
2021 Q3	$831	Buy	+262	New	+$921	﹤0.01%	575

Other funds holding PMCB

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

EPM

Equitec Proprietary Markets Chicago, Illinois $559M AUM 230.29% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Kelly Financial Services's PMCB Position: Q3 2024 in Review

Kelly Financial Services sold out of PharmaCyte Biotech (PMCB) in Q3 2024, closing a stake of 234 shares — an estimated $459 sold.

Kelly Financial Services first reported a position in PMCB in Q3 2021 and held it in 12 quarters. The position peaked at $831 in Q3 2021. 26 funds tracked by Wall St. Rank hold PMCB as of Q3 2024.

Kelly Financial Services reported no remaining PharmaCyte Biotech position as of Q3 2024 after selling out during the quarter.
Kelly Financial Services sold 234 PharmaCyte Biotech shares in Q3 2024, an estimated $459.
Kelly Financial Services first reported a position in PharmaCyte Biotech in Q3 2021 and held it in 12 quarters.
Kelly Financial Services's PharmaCyte Biotech position peaked at $831 in Q3 2021.
26 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2024.

Based on Kelly Financial Services's 13F filing for Q3 2024, filed 9 Oct 2024.